All those affected were women between the ages of 18 and 48, and their symptoms developed 6-13 days after vaccination.
Federal health agencies on Tuesday recommended an immediate pause in the use of Johnson & Johnson’s coronavirus vaccine after six people developed a rare and severe type of blood clot after receiving the shot.
All those affected were women between the ages of 18 and 48, and their symptoms developed 6-13 days after vaccination, the Food and Drug Administration and the Centers for Disease Control and Prevention said in a joint statement.
Johnson & Johnson later Tuesday said it would delay the rollout of its shot in Europe while safety data is reviewed.
More than 6.8 million doses of the single-shot vaccine had been administered in the United States as of Monday, the agencies said. “This announcement will not have a significant impact on our vaccination plan: Johnson & Johnson vaccine makes up less than 5 percent of the recorded shots in arms in the United States to date,” White House Covid-19 response coordinator Jeff Zients said in a statement.
CDC’s vaccine advisory committee will meet Wednesday to review the blood clotting incidents. The FDA, which is set to hold a press conference Tuesday morning, will review the CDC analysis and conduct its own investigation.
“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” the FDA’s top vaccine regulator, Peter Marks, and CDC Principal Deputy Director Anne Schuchat said a joint statement.
You must be logged in to reply to this topic.